Cerivastatin, Sodium Salt (CAS 143201-11-0)
QUICK LINKS
Cerivastatin sodium salt′s mechanism of action involves the inhibition of the enzyme HMG-CoA reductase, which plays a pivotal role in cholesterol production. This action highlights its potential for research in biochemical studies, particularly in understanding cholesterol metabolism and the regulation of lipid levels within organisms. By inhibiting HMG-CoA reductase, cerivastatin sodium curtails cholesterol production, resulting in reduced cholesterol levels. Furthermore, it has been observed to lower triglyceride production while increasing the production of HDL cholesterol. Cerivastatin, sodium salt is a statin. Beyond its primary biochemical activity, the sodium salt form of cerivastatin could have interesting applications in the field of biotechnology, such as in the development of bio-based materials or in environmental bioremediation efforts, where its ability to interact with biological systems could be harnessed in novel ways.
Cerivastatin, Sodium Salt (CAS 143201-11-0) References
- Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits. | Shiomi, M. and Ito, T. 1999. Br J Pharmacol. 126: 961-8. PMID: 10193776
- The pharmacokinetics of cerivastatin in patients on chronic hemodialysis. | Mück, W., et al. 2001. Int J Clin Pharmacol Ther. 39: 192-8. PMID: 11380064
- A cell-based screening system for RNA polymerase I inhibitors. | Tan, X. and Awuah, SG. 2019. Medchemcomm. 10: 1765-1774. PMID: 31803394
- Reduction of plasma cholesterol levels and induction of hepatic LDL receptor by cerivastatin sodium (CAS 143201-11-0, BAY w 6228), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, in dogs. | Yasunobu, Y., et al. 1997. Cardiovasc Drugs Ther. 11: 567-74. PMID: 9358961
- Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor. | Bischoff, H., et al. 1997. Atherosclerosis. 135: 119-30. PMID: 9395280
- Preclinical review of cerivastatin sodium--a step forward in HMG-CoA reductase inhibition. | Bischoff, H., et al. 1998. Atherosclerosis. 139 Suppl 1: S7-13. PMID: 9811153
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Cerivastatin, Sodium Salt, 2.5 mg | sc-207418 | 2.5 mg | $175.00 |